Proliferation_NN
index_NN
as_IN
a_DT
prognostic_JJ
marker_NN
in_IN
breast_NN
cancer_NN
._.

BACKGROUND_NN
._.

The_DT
proliferative_JJ
activity_NN
of_IN
tumors_NNS
has_VBZ
been_VBN
extensively_RB
investigated_VBN
with_IN
different_JJ
approaches_NNS
,_,
among_IN
which_WDT
the_DT
use_NN
of_IN
the_DT
monoclonal_JJ
antibody_NN
Ki-67_NN
represents_VBZ
an_DT
easy_JJ
and_CC
reliable_JJ
means_NN
of_IN
assessing_VBG
cell_NN
proliferation_NN
._.

In_IN
this_DT
study_NN
,_,
the_DT
proliferative_JJ
activity_NN
of_IN
129_CD
primary_JJ
breast_NN
cancers_NNS
was_VBD
investigated_VBN
,_,
and_CC
the_DT
results_NNS
were_VBD
related_JJ
to_TO
prognosis_NN
._.

METHODS_NNS
._.

Tumor_NN
samples_NNS
,_,
obtained_VBN
from_IN
129_CD
patients_NNS
who_WP
underwent_VBD
surgery_NN
between_IN
January_NNP
1987_CD
and_CC
December_NNP
1988_CD
,_,
were_VBD
processed_VBN
for_IN
staining_NN
by_IN
an_DT
immunohistochemical_JJ
procedure_NN
-LRB-_-LRB-
avidin-biotin_NN
complex_NN
-RRB-_-RRB-
._.

The_DT
median_JJ
time_NN
of_IN
observation_NN
was_VBD
42_CD
months_NNS
-LRB-_-LRB-
range_NN
,_,
31-55_CD
months_NNS
-RRB-_-RRB-
._.

Life-table_JJ
analysis_NN
-LRB-_-LRB-
Mantel-Cox_NN
-RRB-_-RRB-
was_VBD
used_VBN
to_TO
assess_VB
the_DT
probability_NN
of_IN
disease-free_JJ
survival_NN
-LRB-_-LRB-
DFS_NN
-RRB-_-RRB-
and_CC
overall_JJ
survival_NN
-LRB-_-LRB-
OS_NN
-RRB-_-RRB-
._.

RESULTS_NNS
._.

Tumors_NNS
with_IN
high_JJ
Ki-67_NN
proliferation_NN
indices_NNS
-LRB-_-LRB-
&gt;_JJR
20_CD
%_NN
-RRB-_-RRB-
were_VBD
associated_VBN
with_IN
a_DT
higher_JJR
4-year_JJ
probability_NN
of_IN
relapse_NN
of_IN
disease_NN
-LRB-_-LRB-
55.3_CD
%_NN
versus_CC
79.1_CD
%_NN
;_:
P_NN
=_JJ
0.003_CD
-RRB-_-RRB-
and_CC
death_NN
-LRB-_-LRB-
71_CD
%_NN
versus_CC
95.6_CD
%_NN
;_:
P_NN
=_JJ
0.00005_CD
-RRB-_-RRB-
when_WRB
compared_VBN
with_IN
tumors_NNS
with_IN
low_JJ
Ki-67_NN
values_NNS
._.

In_IN
addition_NN
,_,
this_DT
proliferative_JJ
parameter_NN
maintained_VBD
its_PRP$
prognostic_JJ
significance_NN
when_WRB
the_DT
patients_NNS
were_VBD
stratified_VBN
according_VBG
to_TO
lymph_NN
node_NN
involvement_NN
,_,
menopausal_JJ
status_NN
,_,
and_CC
nuclear_JJ
estrogen_NN
receptor_NN
content_NN
._.

CONCLUSIONS_NNS
._.

Tumor_NN
proliferative_JJ
activity_NN
as_IN
evaluated_VBN
by_IN
the_DT
monoclonal_JJ
antibody_NN
Ki-67_NN
seems_VBZ
to_TO
be_VB
an_DT
effective_JJ
indicator_NN
of_IN
prognosis_NN
in_IN
breast_NN
cancer_NN
for_IN
DFS_NN
and_CC
OS_NN
._.

